US Stock Insider Trading | Vericel Disclosed 11 Insider Transactions on February 13

K-LinePoet · 2026-03-16T19:33:48+00:00

Vericel Corporation disclosed 11 insider transactions on February 13, 2026, with director MCLAUGHLIN KEVIN F selling 7,000 shares on February 11. The company focuses on regenerative medicine, developing multicellular therapy ixmyelocel-T to treat chronic cardiovascular and cerebrovascular diseases, with clinical data demonstrating good safety and efficacy.

K-LinePoet

2026-03-16 19:33:48

Abstract generation in progress

On February 13, 2026, Vericel (VCEL) disclosed 11 insider trading transactions. Director MCLAUGHLIN KEVIN F sold 7,000 shares on February 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 13, 2026	Executive	Flynn Sean C.	June 30, 2025	Buy	239	36.17	8,644.63
February 13, 2026	Executive	Mara Joseph Anthony Jr	September 30, 2025	Buy	106	26.75	2,835.50
February 13, 2026	Executive	Mara Joseph Anthony Jr	March 31, 2025	Buy	73	37.93	2,768.89
February 13, 2026	Director	MCLAUGHLIN KEVIN F	February 11, 2026	Sell	7,000	34.66	$242,600
February 13, 2026	Director	MCLAUGHLIN KEVIN F	February 11, 2026	Buy	7,000	2.63	18,400
February 13, 2026	Executive	Mara Joseph Anthony Jr	December 31, 2025	Buy	92	26.27	2,416.84
February 13, 2026	Director	Colangelo Dominick	June 30, 2025	Buy	123	36.17	4,448.91
February 13, 2026	Executive	Mara Joseph Anthony Jr	June 30, 2025	Buy	67	36.17	2,423.39
February 13, 2026	Executive	Hopper Jonathan Mark	December 31, 2025	Buy	122	26.27	3,204.94
February 13, 2026	Executive	Flynn Sean C.	March 31, 2025	Buy	267	37.93	10,100.91

[Company Profile]

Vericel Corporation, founded in 1989, is a regenerative medicine company focused on developing innovative cell therapies to repair or regenerate damaged or diseased tissues. The company is developing multi-cell therapies for patients with severe, chronic ischemic cardiovascular and cerebrovascular diseases. The company believes ixmyelocel-T is a multifunctional disease-modifying therapy that includes tissue regeneration, immune modulation, and promotion of angiogenesis. Its proprietary cell manufacturing technology enables the production of multi-cell therapies by expanding adult bone marrow and directly delivering it to damaged tissues. Preclinical and clinical data suggest that ixmyelocel-T may safely and effectively treat severe, chronic ischemic cardiovascular diseases, such as critical limb ischemia (CLI)—the most severe form of peripheral artery disease (PAD)—and dilated cardiomyopathy (DCM)—the third leading cause of heart failure.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes